pharmaphorum
DECEMBER 8, 2014
With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what is next, what are the ramifications for high priced/innovative treatments delivering beneficial outcomes to defined patient populations in the UK and how can pharma navigate seemingly choppy waters of access for rare disease treatments and orphan drugs?
Research Ethics Blog
AUGUST 21, 2014
Following on my recent blog posting about the Facebook emotion-manipulation study , here’s a useful piece from The Atlantic : How Much Should You Know About How Facebook Works? The piece focuses on the ubiquity of constantly-tweaked algorithms in online services such as Google and Facebook. The algorithms such companies use today are quite different from the ones they used 5 years ago, in part because the companies are constantly experimenting and using the results of those experiments to
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Placebo Control
JULY 31, 2014
The good folks down at eyeforpharma have asked me to write a few blog posts in the run-up to their Patient Centered Clinical Trials conference in Boston this September. In my second article - Buzzword Innovation: The Patient Centricity “Fad” and the Token Patient - I went over some concerns I have regarding the sudden burst of enthusiasm for patient centricity in the clinical trial world.
pharmaphorum
OCTOBER 29, 2014
Non-adherence to self-management regimens in diabetes is globally a widespread, costly and ultimately life threatening issue. Reasons for non-adherence are complex as the nature of the condition involves adherence to lifestyle, medication and diet changes, which individuals at times can find difficult to accept and adjust to. It is important to consider that the factors that influence each individual's ability to self manage are often very different and can equally affect patient outcomes, makin
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
pharmaphorum
OCTOBER 22, 2014
A pharmaceutical industry multi-stakeholder interactive discussion on some of the unique challenges faced today in marketing pharma brands effectively to exploit areas of unrealised opportunity, plus what is required from both strategic marketing and research to deliver in view of this.
pharmaphorum
JULY 9, 2014
The global pharmaceutical market passes a significant milestone in 2014: reaching one trillion US dollars in total value. IMS Health forecasts the global market will see a compound average growth rate of between 4 to 7 percent in constant dollar terms to 2018, driven by two very different speed growth engines: at best low single digit value growth in the developed markets, contrasting with largely double digit growth in the power house pharmerging markets.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Placebo Control
JANUARY 12, 2014
This new 10-minute TEDMED talk is getting quite a bit of attention: (if embedded video does not work, try the TED site itself.) In it, Roger Stein claims to have created an approach to advancing drugs through clinical trials that will "fundamentally change the way research for cancer and lots of other things gets done". Because the costs of bringing a drug to market are so high, time from discovery to marketing is so long, and the chances of success of any individual drug are so grim, betting on
Placebo Control
JANUARY 6, 2014
Adam Feuerstein appears to be a generally astute observer of the biotech scene. As a finance writer, he's accosted daily with egregiously hyped claims from small drug companies and their investors, and I think he tends to do an excellent job of spotting cases where breathless excitement is unaccompanied by substantive information. However, Feuerstein's healthy skepticism seems to have abandoned him last year in the case of a biotech called Sarepta Therapeutics , who released some highly promisin
Placebo Control
JANUARY 2, 2014
Big online studies, in search of millions of participants. Back in September, I enrolled in the Heath eHeart Study - an entirely online research study tracking cardiac health. (Think Framingham Heart , cast wider and shallower - less intensive follow-up, but spread out to the entire country.) [In the spirit of full disclosure, I should note that I haven’t completed any follow-up activities on the Heath eHeart website yet.
Research Ethics Blog
SEPTEMBER 16, 2014
The John Hopkins Berman Institute of Bioethics put out a press release today, announcing the pre-release of an article in the Proceedings of the National Academy of Science: In Wake of Uproar Over Facebook’s Emotional Manipulation Study, Bioethics Scholars Say New Rules Are a “Moral Imperative”. It’s not actually news, many would agree, but good to know someone in bioethics has said this in print and that it seems others are paying attention.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Expert insights. Personalized for you.
52 
Let's personalize your content